Form 13G Stoke Therapeutics For: 18 May

Stoke Therapeutics, a biotech company focused on treating rare genetic disorders, has filed a Form 13G with the SEC, revealing a significant stake in the company. The filing indicates a substantial increase in ownership, but the exact percentage of shares held is not disclosed. The move suggests increased investor interest in the company's potential treatments.